The yearly conference brings together leaders throughout the world who are dedicated to advancing treatment options for Alzheimer’s disease (AD). This year, Jim Hendrix presented the LIFE-DSR blood biomarker data at (Clinical Trials in Alzheimer’s Disease) CTAD’s November 2020 digital conference. The LIFE-DSR study is an ongoing natural history study designed to better understand the factories that underlie symptoms of clinical presentation of Down syndrome associated AD (DS-AD). The COVID pandemic provided an opportunity to conduct early analyses on neurodegenerative biomarkers P-tau181, P-tau217 and NfL.
Click on image to download a PDF.
Learn more about the LuMind IDSC Foundation and Eli Lilly and Company partnership.
